106447-64-7Relevant academic research and scientific papers
High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the γ-aminobutyric acid A/benzodiazepine receptor complex
Jacobsen, E. Jon,TenBrink, Ruth E.,Stelzer, Lindsay S.,Belonga, Kenneth L.,Carter, Donald B.,Im, Haesook K.,Im, Wha Bin,Sethy, Vimala H.,Tang, Andy H.,VonVoigtlander, Philip F.,Petke, James D.
, p. 158 - 175 (2007/10/03)
A series of imidazo[1,5-a]quinoxaline amides, carbamates, and ureas which have high affinity for the γ-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies ranging from antagonists to full
Imidazoquinoxaline compounds and their preparation and use
-
, (2008/06/13)
New imidazoquinoxaline compounds having the general formula STR1 wherein STR2 wherein R'' is C 1-6 -alkyl, C 3-7 -cycloalkyl or C 1-6 -alkoxymethyl; and STR3 wherein R 5 is hydrogen or halogen. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and in improving the cognitive function of the brain of mammals.
Imidazothienopyrimidines useful in psychopharmaceutical preparations
-
, (2008/06/13)
New heterocyclic compounds having the general formula STR1 wherein STR2 wherein R'' is C 1-6 -alkyl, C 3-7 -cycloalkyl or C 1-6 -alkoxymethyl;R 4 is C 1-6 -alkyl;--S-- is STR3 and wherein R 5 and R 6 independently are hydrogen, C 1-6 -alkyl, or aryl.The c
Benzodiazepine derivatives and their preparation and use
-
, (2008/06/13)
New benzodiazepine derivatives of the general formula STR1 wherein X 1 and X 2 independently are STR2 wherein R 1 is C 1-3 -alkyl, C 3-5 -cycloalkyl, C 1-3 -alkoxymethyl, C 1-3 -hydroxyalkyl, or aryl,R 4 is hydrogen, andR 5 is C 1-6 -alkyl, or wherein R 4 and R 5 together form a 2-4 membered alkylene chain.The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.
OXADIAZOLYLIMIDAZOBENZODIAZEPINE, COMPOSITIONS, AND METHOD
-
, (2008/06/13)
The application discloses novel benzodiazepine agonist compounds, namely, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-7-halo-4H-imidazo [1,5-a][1,4]benzodiazepines, pharmaceutical compositions thereof, and a method of ameliorating central nervous system ailments therewith, especially convulsions and anxiolytic states. A novel intermediate and process for their production are also disclosed.
